Skip to content
Catalyst

PapersPMID:40511533

Melatonin Mitigates Sarcopenic Obesity via Microbiota and Short-Chain Fatty Acids: Evidence From Epidemiologic and In Vivo Studies.

Journal of cachexia, sarcopenia and muscle2025The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, insufficient evidencelowersLDL cholesterol
  2. Finding, insufficient evidencelowersBody weight gain over a feeding or growth period
Study, every finding
animal · not in humans · 4 months
Dose studied, every finding
10 mg/kg melatonin daily by oral administration, 16 weeks

What moved

How to read these marks →
  • Decreases LDL cholesterol

    insufficient

    “In addition, HFD‐induced increases in the levels of total cholesterol (TC), triglyceride (TG) and low‐density lipoprotein cholesterol (LDL‐C) in serum were reduced by MLT (Figure S2B, p < 0.05).”
    Population
    12-month-old female Sprague-Dawley rats fed a high-fat diet (HFD) for 16 weeks, melatonin versus vehicle in HFD-fed rats; serum after overnight fast
  • Decreases body weight gain over a feeding or growth period

    insufficient

    “HFD significantly increased the body weight of rats, whereas HFD‐induced body weight gain was reduced by MLT (Figure S1C, p < 0.05).”
    Population
    12-month-old female Sprague-Dawley rats fed a high-fat diet (HFD) for 16 weeks, melatonin (MLT) versus vehicle in HFD-fed rats; a normal-diet control group was also housed

Study record

Design
animal study, in vivo
Species
animal / mixed
Population
Older adults with sarcopenic obesity (SO) and age- and sex-matched controls (case-control, Shenzhen Ageing Cohort); and 12-month-old female Sprague-Dawley rats fed a high-fat diet (HFD) with oral melatonin, faecal microbiota transplantation, or short-chain fatty acid treatment
Participants
not reported
Comparator
placebo
Duration
112 days
Endpoints measured
25